Specialized PET scan picks up endometrial cancer


Comparative uptake of two radiotracers allows characterization of tumor.

PET imaging may be the missing link in the chain needed to find endometrial carcinoma and successfully manage patients with the disease.

This carcinoma is among the most common malignant tumors affecting women. If the disease is caught early, however, the five-year survival rate is better than 90%. Research at the University of Fukui in Japan has shown that a specialized form of PET, called estrogen receptor expression imaging, may find the disease before it reaches advanced stages while eliminating the need for biopsies and other interventions that can render women infertile.

In the study, published in the October issue of The Journal of Nuclear Medicine, PET imaged multiple facets of the tumor phenotype, specifically estrogen receptor expression and glucose metabolism, in 22 patients with endometrial adenocarcinoma and nine patients with endometrial hyperplasia, a thickening of the uterine lining that is a risk factor for developing endometrial cancer.

Data obtained from these PET scans provided the basis for predicting tumor growth patterns, allowing physicians to plan the most appropriate therapeutic treatment strategy, according to Dr. Hidehiko Okazawa, professor in the division of medical imaging at the University of Fukui. Okazawa and colleagues compared differences in the accumulation of two different PET radiotracers: F-18 fluoroestradiol (F-18 FES), a tracer that has been used successfully in diagnosing breast cancer, and 18F-fluorodeoxyglucose (F-18 FDG). Through this comparison, they were able to predict pathologic stages and aggressiveness of tumors with 86% accuracy, according to the researchers.

For endometrial cancer, estrogen receptor expression is related to endocrine responsiveness and indicated by FES uptake. Poorly differentiated tumors often have increased and abnormal breakdown of glucose, indicated by FDG. The combination of the two, as indicated by the study, was better than either alone at indicating the aggressiveness of the tumor.

Related Videos
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Pembrolizumab combined with carboplatin and paclitaxel resulted in response rates in patients with recurrent endometrial cancer.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Related Content